C12Y 207/01026
Riboflavin kinase
Official title: Riboflavin kinase (2.7.1.26)
C12Y207/01026 (Riboflavin kinase) appears on 1 US grants and 5 published applications in this corpus.
Search patents in C12Y- Granted patents
- 1
- Published applications
- 5
- Assignees
- 2
- Inventors
- 37
- Latest grant
- 7 Jul 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2005 | 0 | 3 |
| 2006 | 0 | 0 |
| 2007 | 0 | 0 |
| 2008 | 0 | 0 |
| 2009 | 0 | 0 |
| 2010 | 0 | 0 |
| 2011 | 0 | 0 |
| 2012 | 0 | 0 |
| 2013 | 0 | 0 |
| 2014 | 0 | 0 |
| 2015 | 0 | 0 |
| 2016 | 0 | 0 |
| 2017 | 0 | 0 |
| 2018 | 0 | 0 |
| 2019 | 0 | 0 |
| 2020 | 0 | 0 |
| 2021 | 0 | 0 |
| 2022 | 0 | 0 |
| 2023 | 0 | 0 |
| 2024 | 0 | 1 |
| 2025 | 0 | 1 |
| 2026 | 1 | 0 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Listeria Variants and Methods of Use Thereof13 Mar 2025US 2025/0082741 A1
- Limosilactobacillus reuteri strain with high riboflavin production and uses thereof11 Jan 2024US 2024/0011067 A1Universiteit Antwerpen
- Novel purified polypeptides from bacteria29 Sep 2005US 2005/0214773 A1Affinium Pharmaceuticals, Inc.
- Novel purified polypeptides from Streptococcus pneumoniae25 Aug 2005US 2005/0187718 A1Affinium Pharmaceuticals, Inc.
- Novel purified polypeptides from bacteria18 Aug 2005US 2005/0181388 A1Affinium Pharmaceuticals, Inc.
Most cited
By later US patents
No patent in this class has been cited by a later US patent yet.